Graves' Disease malady

NIH Rare Diseases: Graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). It is caused by an abnormal immune system response that causes the thyroid gland to produce too much thyroid hormones. Graves disease is the most common cause of hyperthyroidism and occurs most often in women over age 20. However, the disorder may occur at any age and may affect males as well. Treatment may include radioiodine therapy, antithyroid drugs, and/or thyroid surgery.³⁰

MalaCards: Graves' Disease, also known as graves disease, is related to autoimmune thyroiditis and goiter. An important gene associated with Graves' Disease is SLC25A16 (solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16), and among its related pathways are Viral myocarditis and Cell adhesion molecules (CAMs). The compounds allergens and cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include thyroid gl, bone marrow and lymph node, and related mouse phenotypes are respiratory system and hematopoietic system.

Disease Ontology: An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located in thyroid gland.⁶

Wikipedia: Graves\' disease is an autoimmune disease where the thyroid is overactive, producing an excessive amount...⁴⁴ more...

Aliases & Descriptions:

graves' disease 6 30 graves disease 8 32 43 exophthalmic goiter 6 30 toxic diffuse goiter with exophthalmos (disorder) 6 graves' hyperthyroidism 30

toxic diffuse goiter 43 basedow disease 30 grave's disease 6 parry disease 30

Disease types for graves' disease family:

graves disease 3	graves disease 1
graves disease 2	graves disease 4

Diseases related to graves' disease by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1027)

id	Related Disease	Score	Top Affiliating Genes
1	autoimmune thyroiditis	35.8	SERPINA7, LMOD1, SDHA, CHKB, ATP5O, CD59
2	goiter	34.4	SELE, SELL, SERPINA7, LMOD1, BGLAP, PAX8
3	hypothyroidism	33.5	RETN, IGFBP3, IFNA1, IFNA2, IFNB1, TRH
4	hyperthyroidism	33.4	RETN, KITLG, VWF, SELE, SELL, SERPINA7
5	immunodeficiency	33.2	PDCD1, KIR3DL1, SELL, LMOD1, BMP6, SDHA
6	multinodular goiter	33.1	GSR, IL1A, IL1B, IFNG, GNAS, CAT
7	thyroid cancer	33.0	PAX8, CALCA, TPO, PPARG, KRT19, TSHR
8	type 1 diabetes mellitus	32.9	PDCD1, RETN, KIR3DL1, SERPINA7, NAGLU, VDR
9	nodular goiter	32.9	GSR, IL6R, IFNG, ICAM1, CALCA, TRH
10	addison's disease	32.8	PDCD1, VDR, BGLAP, CD79A, CD274, FOXP3
11	rheumatoid arthritis	31.5	MTHFR, CD40, MICA, FCRL3, IL10, IL1B
12	thyrotoxicosis	31.2	LMOD1, BGLAP, MTHFR, CGA, CD36, INS
13	myxedema	31.1	CHKB, CD79A, TPO, CTLA4, TSHR, TG
14	subacute thyroiditis	31.1	NAGLU, BGLAP, BAK1, FGF2, IL1B, IL1R1
15	multiple sclerosis	31.0	CD40, MICA, IL12A, IL1A, IL1B, IL1RN
16	systemic lupus erythematosus	31.0	PDCD1, VWF, SELE, VCAM1, MPO, CD28
17	papillary thyroid carcinoma	31.0	PAX8, BAX, CALCA, ESR2, TPO, SPP1
18	thyroiditis	30.3	RETN, KITLG, VWF, GC, SELE, SERPINA7
19	nontoxic goiter	30.1	BGLAP, FASLG, TRH, TPO, TSHR, TG
20	acute lymphoblastic leukemia	29.8	KITLG, KIR3DL1, SELL, BCL2, LEF1, MTHFR
21	allergic rhinitis	29.8	SELE, VCAM1, IL13, IL4, IL5, IGES
22	paralysis	29.2	KCNJ18, CHKB, CD274, INS, IL10, IL16
23	hyperthyroxinemia	29.1	SERPINA7, CD79A, ALB, TRH, TPO, TTR
24	hypergammaglobulinemia	29.0	CD79A, CD40LG, CD40, IL10, IL2RA, IL5
25	diabetes insipidus	28.4	VWF, CGA, MPO, CD1A, INS, IGF1
26	hepatitis c	28.1	CD28, CD69, CD40LG, IRF1, GSR, IL10
27	myasthenia gravis	27.9	PDCD1, BCL2, CHKB, CD28, CD79A, CD86
28	hepatitis	27.5	GSR, IL2RB, FASLG, FAS, IFNA1, IFNA2
29	vitiligo	26.8	KITLG, BTNL2, VDR, BMP6, BAX, MPO
30	mediastinitis	26.2	SELE, MYC, CHKB, CGA, MPO, CD79A
31	rhinitis	26.0	RETN, KITLG, SELE, SELL, VCAM1, BGLAP
32	severe combined immunodeficiency	25.5	KITLG, MYC, BCL2, BAX, CD28, CD40LG
33	combined immunodeficiency	25.4	KITLG, MYC, BCL2, BAX, CD28, CD40LG
34	glucose intolerance	25.1	RETN, VCAM1, CD36, INS, IL6, IL6R
35	diabetes mellitus	24.8	PDCD1, PDCD1LG2, RETN, KIR2DS5, KIR3DS1, KIR3DL1
36	peripheral neuropathy	24.6	RETN, SELE, MTHFR, MPO, CD40LG, INS
37	conjunctivitis	24.5	KITLG, VDR, BCL2, CGA, MPO, CD79A
38	myopathy	24.5	BTD, SELE, VCAM1, BCL2, CHKB, BAX
39	purpura	23.9	VWF, SELE, VCAM1, BMP6, MTHFR, MPO
40	carcinoma	23.9	PDCD1, PDCD1LG2, RETN, WARS, KIR2DS5, KIR2DL1
41	thyroid carcinoma	23.7	KITLG, SELE, SELL, VDR, VCAM1, MYC
42	pituitary adenoma	23.0	SERPINA7, LMOD1, MYC, BMP6, BCL2, BAX
43	pheochromocytoma	22.9	MYC, BCL2, SDHA, CD36, CDKN1B, FOS
44	arthritis	22.6	PDCD1, PDCD1LG2, RETN, WARS, KIR2DS3, KIR2DL1
45	lupus erythematosus	22.5	PDCD1, PDCD1LG2, RETN, KIR2DS3, KIR2DS5, KIR2DL1
46	osteoporosis	22.4	GC, SELE, VDR, BMP6, BGLAP, MTHFR
47	twinning	22.3	RETN, VWF, BTD, VDR, LMOD1, BGLAP
48	glomerulonephritis	21.5	KITLG, VWF, NAGLU, VCAM1, BMP6, BGLAP
49	adenoma	21.2	RETN, KITLG, SERPINA7, VDR, LMOD1, MYC
50	lymphoblastic leukemia	21.2	KITLG, KIR3DL1, VWF, SELL, VDR, MYC

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to graves' disease:

²²

FMA organs/tissues related to graves' disease:

¹¹

MGI Mouse Phenotypes related to graves' disease:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	11.2	SELL, UACA, FGF23, IL12A, CCR4, CALCA
2	hematopoietic system phenotype	MP:0005397	10.8	PDCD1, PDCD1LG2, BCL2, BAK1, UACA, CD28
3	endocrine/exocrine gland phenotype	MP:0005379	10.7	SELL, PAX8, UGDH, UACA, CDKN1B, CD40LG
4	craniofacial phenotype	MP:0005382	10.6	KITLG, NAGLU, PAX8, LEF1, UGDH, ITGA4
5	liver/biliary system phenotype	MP:0005370	9.7	RETN, UACA, CD36, INS, IL1R1, IL2
6	reproductive system phenotype	MP:0005389	9.6	VDR, PAX8, LEF1, UACA, B2M, CGA
7	immune system phenotype	MP:0005387	9.5	VWF, SELL, NAGLU, VDR, BAK1, UACA
8	limbs/digits/tail phenotype	MP:0005371	9.4	KITLG, VDR, LEF1, CHKB, BAK1, BAX
9	renal/urinary system phenotype	MP:0005367	9.2	PDCD1, BTD, NAGLU, PAX8, BCL2, BAK1
10	behavior/neurological phenotype	MP:0005386	9.2	BTD, SELE, NAGLU, CHKB, XRCC1, CD86
11	nervous system phenotype	MP:0003631	9.1	PDCD1, KITLG, VWF, NAGLU, MYC, PAX8
12	mortality/aging	MP:0010768	9.1	PDCD1, PDCD1LG2, KITLG, VWF, SELE, NAGLU
13	digestive/alimentary phenotype	MP:0005381	8.8	KITLG, VWF, VDR, MYC, BCL2, UGDH
14	no phenotypic analysis	MP:0003012	8.7	PDCD1LG2, VCAM1, MYC, PAX8, MTHFR, CD79A
15	integument phenotype	MP:0010771	8.4	KITLG, BTD, MYC, BCL2, LEF1, UACA
16	hearing/vestibular/ear phenotype	MP:0005377	8.0	KITLG, NAGLU, VDR, MYC, PAX8, BCL2
17	growth/size phenotype	MP:0005378	7.7	KITLG, BTD, SELE, NAGLU, VDR, VCAM1
18	normal phenotype	MP:0002873	7.7	SELE, MYC, UGDH, BAK1, XRCC1, CD28
19	skeleton phenotype	MP:0005390	7.2	KITLG, GC, NAGLU, VDR, MYC, BMP6
20	vision/eye phenotype	MP:0005391	7.0	PDCD1, KITLG, BTD, SELE, NAGLU, BCL2
21	cellular phenotype	MP:0005384	6.2	PDCD1, PDCD1LG2, KITLG, VWF, SELE, SELL
22	tumorigenesis	MP:0002006	5.7	PDCD1LG2, KITLG, SELL, MYC, BCL2, XRCC1
23	adipose tissue phenotype	MP:0005375	5.7	RETN, MYC, BCL2, LEF1, CD36, CDKN1B
24	muscle phenotype	MP:0005369	5.6	PDCD1, BTD, MYC, BCL2, CHKB, BAX
25	homeostasis/metabolism phenotype	MP:0005376	5.4	PDCD1LG2, RETN, KITLG, VWF, GC, BTD
26	cardiovascular system phenotype	MP:0005385	5.2	PDCD1, KITLG, VWF, SELE, SELL, NAGLU

Articles related to graves' disease:

(show top 50)    (show all 599)

id	Title	Authors	Year	Affiliating Genes
1	Resistance to thyroid hormone in a patient with coexi sting Graves' disease. (20151830)	Sivakumar T.... Chaidarun S.	2010	THRB
2	Expression of IFNalpha-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease. (20015465)	Kuang M.... Li L.	2010	IFNA1
3	Association study between methylenetetrahydrofolate r eductase gene polymorphisms and Graves' disease. (20941748)	Mao R.... Fu S.	2010	MTHFR
4	Copper(II) complexes of methimazole, an anti Grave's disease drug. Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor. (20012553)	Urquiza N.M.... Ferrer E.G.	2010	ALPP
5	Regulatory T cells in Graves' disease. (19222488)	Pan D.... De Groot L.J.	2009	TNFRSF18
6	Enhancement of experimental Graves' disease by intranasal administration of a T cell epitope of the thyrotropin receptor. (18234558)	Arima T.... Kohno Y.	2008	TSHR
7	Thyrotoxicosis factitia masquerading as recurrent Graves' disease: endogenous antibody immunoassay interference, a pitfall for the unwary. (18482926)	Jahagirdar V.R.... Singh B.M.	2008	TG
8	Graves' disease in Brazilian children and adults: lack of genetic association with CTLA-4 +49A>G polymorphism. (18493148)	Namo Cury A.... Monte O.	2008	CTLA4
9	Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. (17371467)	Brand O.J.... Gough S.C.	2007	IL2RA
10	The A946T polymorphism in the interferon induced helicase gene does not confer susceptibility to Graves' disease in Chinese population. (18026693)	Zhao Z.F.... Zhao Y.J.	2007	IFIH1
11	Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. (17244787)	Antonelli A.... Ferrannini E.	2007	CXCL10
12	The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells. (17823263)	McLachlan S.M.... Rapoport B.	2007	TPO, TSHR, TG
13	New HLA DRB1 and DQB1 haplotypes in a pedigree of familial Graves' disease in Japan. (17785916)	Sasaki M.... Ishikawa S.E.	2007	HLA-DQB1, HLA-DRB1
14	Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Graves' disease. (16912510)	Mochizuki Y.... Monden T.	2006	TNFRSF11B
15	The association between HLA class II haplotype with Graves' disease in Thai population. (16451208)	Wongsurawat T.... Hirankarn N.	2006	HLA-DQA1, HLA-DQB1, HLA-DRB1
16	Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1*07. (16756466)	Kula D.... Jarzab B.	2006	CTLA4, HLA-DRB1
17	Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. (16410300)	Gianoukakis A.G.... Smith T.J.	2006	IGF1R, CCL5, IL16
18	Association of a C/T single-nucleotide polymorphism in the 5' untranslated region of the CD40 gene with Graves' disease in Japanese. (16756465)	Ban Y.... Ban Y.	2006	CD40
19	Thyroid sialyltransferase mRNA level and activity are increased in Graves' disease. (16053379)	Kiljanski J.... Bartoszewicz Z.	2005	ST6GAL1, ST3GAL1
20	Graves' disease and stiff-person (stiff-man) syndrome: case report and literature review. (16006304)	Orija I.B.... Zimmerman R.S.	2005	TSHR
21	A C/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese. (16127217)	Mukai T.... Yamada K.	2005	CD40
22	Regression mapping of association between the human leukocyte antigen region and Graves disease. (15558498)	Simmonds M.J.... Gough S.C.	2005	HLA-DQA1, HLA-DRB1
23	Role of the CD40 locus in Graves' disease. (15307939)	Houston F.A.... Pearce S.H.	2004	CD40LG, CD40
24	A polymorphism of interferon-gamma gene associated with changes of anti-thyrotropin receptor antibodies induced by antithyroid drug treatment for Graves' disease in Japanese patients. (15068623)	Fukutani T.... Yamada K.	2004	IFNG
25	CTLA-4 gene polymorphism and its association with Graves' disease in the Lebanese population. (15182328)	Nakkash-Chmaisse H.... Salti I.	2004	CTLA4
26	Antibodies to glutamic acid decarboxylase in patients with Graves disease (15600194)	An Z.... Zhao G.	2003	TG
27	Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease. (14557478)	Kretowski A.... Kinalska I.	2003	ICAM1
28	Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination. (12488353)	Rao P.V.... Banga J.P.	2003	TSHR
29	CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. (12780750)	Vaidya B.... Pearce S.H.	2003	CTLA4
30	CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. (14751028)	Takara M.... DeGroot L.J.	2003	CTLA4
31	Pax-8 expression correlates with type II 5' deiodinase expression in thyroids from patients with Graves' disease. (12699588)	Ambroziak M.... Nauman A.	2003	PAX8, DIO2, NKX2-1
32	Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease. (11683428)	JA^dar E.... Hawkins F.	2001	BGLAP
33	No association of an interleukin 4 gene promoter polymorphism with Graves' disease in the United Kingdom. (11502824)	Heward J.M.... Gough S.C.	2001	IL4
34	Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter. (11453524)	Bossowski A.... Urban M.	2001	IL6R
35	Novel TSHR germline mutation (Met463Val) masquerading as Graves' disease in a large Welsh kindred with hyperthyroidism. (11201847)	Fuhrer D.... Ludgate M.	2000	TSHR
36	Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. (10341866)	Maugendre D.... Allannic H.	1999	TPO
37	Sharing of susceptibility loci between autoimmune diseases: lack of association of the insulin gene region with Graves' disease. (10211611)	Allahabadia A.... Gough S.C.	1999	INS
38	Graves' disease (clinical aspects of Graves' disease ) (10483245)	Iitaka M.	1999	CSF3
39	A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease. (10523002)	Sato A.... Kamijo K.	1999	IGHE
40	CD30 expression and interleukin-4 and interferon-gamma production of intrathyroidal lymphocytes in Graves' disease. (10319937)	Okumura M.... Amino N.	1999	IL4, IFNG
41	The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. (9510119)	Michelangeli V.... Colman P.	1998	TSHR
42	Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease. (9578815)	Iitaka M.... Ito K.	1998	CSF3
43	Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy. (8980891)	Ozata M.... Gundogan M.A.	1996	ICAM1
44	Immunoglobulins from Graves' disease patients stimulate phospholipase A2 and C systems in FRTL-5 and human thyroid cells. (8890723)	Atwa M.A.... Burman K.D.	1996	PLA2G6
45	T-cell recognition of residue 158-176 in thyrotropin receptor confers risk for development of thyroid autoimmunity in siblings in a family with Graves' disease. (9001188)	Soliman M.... DeGroot L.J.	1996	TSHR
46	Heterogeneous responses of recombinant human thyrotropin receptor to immunoglobulins from patients with Graves' disease. (1354957)	Endo T.... Onaya T.	1992	TSHR
47	Studies on the renal handling of urea nitrogen, crea tinine, water and electrolytes in hyperthyroid patients with Graves' disease (1868921)	Shirota T.	1991	CHKB
48	Peripheral blood T lymphocyte sensitization to thyroid microsomal antigen from patients with Graves' disease negative for circulating anti-thyroid microsomal antibodies. (2078913)	Matsubayashi S.... VolpAc R.	1990	TPO
49	Implication of the HLA-DRB3 gene in Graves' disease: predominance of allele Dw24. (1979072)	Semana G.... Fauchet R.	1990	HLA-DRB3
50	Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. (2375236)	Winsa B.... Karlsson F.A.	1990	TG

Genes related to graves' disease according to GeneCards:

(show top 50)    (show all 251)

id	Symbol	Description	Score	GeneCards Section Context
1	SLC25A16	solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16	11.1	Orthologs, Publications, Transcripts, Aliases & Descriptions (show all 7 sections) Domains & Families, Proteins, Summaries
2	CTLA4	cytotoxic T-lymphocyte-associated protein 4	11.1	Functions, Summaries, Publications
3	GRD1	Graves disease, susceptiblity to, 1	11.1	Aliases & Descriptions
4	GRDX	Graves disease, susceptibility to, X-linked	11.1	Aliases & Descriptions, Publications
5	GRD2	Graves disease, susceptibility to, 2	11.1	Publications, Aliases & Descriptions
6	PTPN22	protein tyrosine phosphatase, non-receptor type 22 (lymphoid)	11.1	Publications, Summaries
7	LMOD1	leiomodin 1 (smooth muscle)	11.1	Publications, Summaries
8	TG	thyroglobulin	11.1	Publications, Summaries
9	DIO2	deiodinase, iodothyronine, type II	11.1	Summaries, Publications
10	GC	group-specific component (vitamin D binding protein)	11.0	Publications
11	IDDM12	insulin-dependent diabetes mellitus 12	11.0
12	TSHR	thyroid stimulating hormone receptor	11.0	Publications, UniProt Related
13	IGES	immunoglobulin E concentration, serum	11.0	Publications
14	HTLVR	human T-cell leukemia virus (I and II) receptor	11.0	Publications
15	TNFRSF4	tumor necrosis factor receptor superfamily, member 4	11.0	Publications
16	ATP5O	ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit	11.0	Publications
17	TPO	thyroid peroxidase	11.0	Publications
18	TNFRSF9	tumor necrosis factor receptor superfamily, member 9	11.0	Publications
19	HLA-DRB3	major histocompatibility complex, class II, DR beta 3	11.0	Publications
20	CYP27B1	cytochrome P450, family 27, subfamily B, polypeptide 1	11.0	Publications
21	PSMB9	proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2)	11.0	Publications
22	TAP1	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	11.0	Publications
23	AIRE	autoimmune regulator	11.0	Publications
24	SERPINA7	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7	11.0	Publications
25	CD69	CD69 molecule	11.0	Publications
26	CXCR3	chemokine (C-X-C motif) receptor 3	11.0	Publications
27	FGF23	fibroblast growth factor 23	11.0	Publications
28	IL16	interleukin 16	11.0	Publications
29	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1	11.0	Publications
30	PAX8	paired box 8	11.0	Publications
31	CD40	CD40 molecule, TNF receptor superfamily member 5	11.0	Publications
32	TAP2	transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)	11.0	Publications
33	LTA	lymphotoxin alpha (TNF superfamily, member 1)	11.0	Publications
34	CD80	CD80 molecule	11.0	Publications
35	FASLG	Fas ligand (TNF superfamily, member 6)	11.0	Publications
36	NKX2-1	NK2 homeobox 1	11.0	Publications
37	IL6R	interleukin 6 receptor	11.0	Publications
38	IL4R	interleukin 4 receptor	11.0	Publications
39	IL4	interleukin 4	11.0	Publications
40	GAD2	glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa)	11.0	Publications
41	FAS	Fas (TNF receptor superfamily, member 6)	11.0	Publications
42	ADRB2	adrenoceptor beta 2, surface	11.0	Publications
43	FLNB	filamin B, beta	11.0	Publications
44	VDR	vitamin D (1,25- dihydroxyvitamin D3) receptor	11.0	Publications
45	IRF1	interferon regulatory factor 1	11.0	Publications
46	ICAM1	intercellular adhesion molecule 1	11.0	Publications
47	CD59	CD59 molecule, complement regulatory protein	11.0	Publications
48	CD28	CD28 molecule	11.0	Publications
49	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1	11.0	Publications
50	CD86	CD86 molecule	11.0	Publications

Pathways related to graves' disease according to GeneDecks:

(show top 50)    (show all 128)

id	Pathway	Score	Top Affiliating Genes
1	Viral myocarditis20	11.5	CD28, CD86, CD40LG, CD80, CD40, CD55
2	Cell adhesion molecules (CAMs)20	11.4	PDCD1LG2, SELL, CD28, CD86, CD80, CD40
3	Antigen processing and presentation20	11.4	KIR2DS3, KIR2DS5, KIR2DL1, KIR2DL3, KIR2DS4, KIR3DL1
4	Immune System38	11.3	PDCD1, PDCD1LG2, KIR2DS5, KIR2DL1, KIR2DL3, KIR3DS1
5	Akt Signaling36	11.3	CD28, CD80, ITGAL, ITGB2, FGF23, IL10
6	Graft-versus-host disease20	11.2	KIR2DL1, KIR2DL3, KIR3DL1, KIR2DL5A, KIR2DL2, CD28
7	Autoimmune thyroid disease20	11.1	CGA, CD28, CD86, CD40LG, CD80, CD40
8	Natural killer cell mediated cytotoxicity20	11.0	KIR2DS3, KIR2DS5, KIR2DL1, KIR2DL3, KIR2DS4, KIR3DL1
9	Type I diabetes mellitus20	11.0	CD28, CD86, CD80, INS, IL12A, IL1A
10	Regulation of eIF4 and p70S6K36	10.8	BAX, CD80, ITGA4, ITGAL, ITGB2, FGF23
11	RAR-Gamma-RXR-Alpha Degradation36	10.7	CD80, IL12A, IL16, IL2, IL3, IL9
12	Allograft rejection20	10.6	CD28, CD86, CD40LG, CD80, CD40, IL10
13	Asthma20	10.6	CD40LG, CD40, IL10, IL13, IL3, IL4
14	Intestinal immune network for IgA production20	10.4	CD28, CD86, CD40LG, CD80, CD40, ITGA4
15	Hematopoietic cell lineage20	10.3	KITLG, CD36, CD59, CD1B, CD1A, CD1C
16	IL-6 Pathway36	10.3	BMP6, BAX, CD80, IL10, IL12A, IL16
17	Jak-STAT signaling pathway20	10.3	MYC, IL10, IL12A, IL13, IL2, IL2RA
18	Influenza A20	10.2	IL12A, IL18, IL1A, IL1B, IL6, IL8
19	Leishmaniasis20	10.1	ITGA4, ITGB2, FOS, FCGR2A, IL10, IL12A
20	Endothelin-1 Signaling Pathway36	10.0	MYC, BMP6, CD80, IL10, IL12A, IL13
21	Rheumatoid arthritis20	9.9	CD28, CD86, CD80, ITGAL, ITGB2, FOS
22	NFAT Signaling and Lymphocyte Interactions36	9.9	BMP6, BCL2, BAX, CD80, IL12A, IL13
23	Transcription Role of VDR in regulation of genes involved in osteoporosis10	9.8	VDR, BGLAP, CGA, FOS, IL1A, IL1B
24	Transcription_Role of VDR in regulation of genes involved in osteoporosis41	9.8	VDR, BGLAP, CGA, FOS, IL1A, IL1B
25	Toxoplasmosis20	9.8	BCL2, CD40LG, CD40, IL10, IL12A, CCR5
26	Malaria20	9.7	SELE, VCAM1, CD36, CD40LG, CD40, ITGAL
27	OX40 Pathway36	9.7	BCL2, IL13, IL4, IL5, IL9, TNFRSF4
28	Measles20	9.6	CD28, CDKN1B, IL12A, IL13, IL1A, IL1B
29	Cytokine-cytokine receptor interaction20	9.5	KITLG, CD40LG, CD40, IL10, IL12A, IL13
30	PGC1Alpha Pathway36	9.5	BMP6, BCL2, BAX, CD80, IL12A, IL13
31	Toll-like receptor signaling pathway20	9.5	CD86, CD80, CD40, FOS, IL12A, IL1B
32	Cytokine Network36	9.4	IL10, IL12A, IL13, IL16, IL18, IL1A
33	STAT3 Pathway36	9.2	MYC, BMP6, BCL2, BAX, CD28, CD80
34	all-trans-Retinoic Acid Signaling in Brain36	9.1	BMP6, BCL2, BAX, CD80, IL10, IL12A
35	Tuberculosis20	9.0	VDR, BCL2, BAX, ITGB2, FCGR2A, IL10
36	ERK Signaling36	9.0	KITLG, MYC, BMP6, CD80, ITGA4, ITGAL
37	SOCS Pathway36	8.9	BMP6, BCL2, BAX, CD80, INS, FGF2
38	MIF Mediated Glucocorticoid Regulation36	8.8	BMP6, BCL2, BAX, CD80, IL10, IL12A
39	Chagas disease (American trypanosomiasis)20	8.7	FOS, IL10, IL12A, IL1B, IL2, IL6
40	MIF Regulation of Innate Immune Cells36	8.5	BMP6, BCL2, BAX, CD80, FOS, IL10
41	PEDF Induced Signaling36	8.5	BMP6, BCL2, BAX, CD80, FOS, IL10
42	Tec Kinases Signaling36	8.4	KITLG, BMP6, BCL2, BAX, CD28, CD80
43	Glucocorticoid Receptor Signaling36	8.4	BMP6, BCL2, BAX, CD80, FOS, IL10
44	Rho Family GTPases36	8.1	KITLG, BMP6, BCL2, BAX, CD80, ITGA4
45	PAK Pathway36	8.0	KITLG, BMP6, BCL2, BAX, CD80, FGF2
46	TGF-Beta Pathway36	8.0	KITLG, BMP6, BCL2, BAX, CD80, FOS
47	MAPK Family Pathway36	8.0	KITLG, BMP6, BCL2, BAX, CD80, FGF2
48	Molecular Mechanisms of Cancer36	7.9	KITLG, MYC, BMP6, BCL2, BAK1, BAX
49	p38 Signaling36	7.8	KITLG, BMP6, BCL2, BAX, CD28, CD80
50	JAK-STAT Pathway36	7.3	KITLG, MYC, BMP6, BCL2, BAX, CD80

Compounds related to graves' disease according to GeneDecks:

(show top 50)    (show all 472)

id	Compound	Score	Top Affiliating Genes
1	allergens32	11.5	PDCD1, CD79A, CD69, CD86, CD40LG, CD80
2	cyclophosphamide32 34 9 9	13.8	ITGA4, ITGAL, ITGB2, APOH, TRB@, CXCL9
3	endotoxin32	10.6	RETN, GC, SELL, CHKB, CD86, CD40
4	phosphorus32	10.6	NAGLU, VDR, B2M, FGF23, ALPP, CALCA
5	polysaccharide32	10.5	KITLG, SELE, SELL, VCAM1, BMP6, CHKB
6	methimazole32 9 9	12.4	VWF, SELE, SELL, SERPINA7, BGLAP, CD69
7	melphalan32 9 9	12.4	CHKB, CD79A, GSTP1, IL4, IGF1R, IFNA1
8	pge232	10.3	SELE, VCAM1, CGA, CD69, CD86, CD83
9	vitamin-e32	10.3	NAGLU, VCAM1, B2M, CD40, GSR, GSTT1
10	rapamycin32 42	11.3	KITLG, SELL, CD86, CD80, FOXP3, INS
11	manganese superoxide32	10.3	VCAM1, XRCC1, CD40, GSR, GSTM1, GSTP1
12	agar32	10.3	KITLG, CDKN1B, CD40LG, FGF2, IL9, IGF1R
13	methylcellulose32	10.3	KITLG, CD59, FGF2, IL1A, IL3, IL4
14	tarc32	10.2	ITGA4, IL10, IL13, IL18, IL1A, IL4
15	gnrh32	10.1	KITLG, SELL, CD69, MKI67, INS, FASLG
16	cysteine32	10.1	KIR2DS4, BTD, NAGLU, VDR, LMOD1, BGLAP
17	isoproterenol32 9 9	12.1	SELL, ITGAL, FGF2, IL13, IL1A, IL3
18	simvastatin32 34 42 9 18 9	15.0	KITLG, VWF, SELE, SELL, VCAM1, BMP6
19	ifn-alpha32	9.9	IRF1, IL10, IL13, IL18, IL2, IL2RA
20	vincristine32 34 9 9	12.9	ITGA4, FGF2, IFNA1, IFNB1, CALCA, TXN
21	epinephrine32 9 18 9	12.8	KITLG, SELE, SELL, BMP6, CHKB, CGA
22	salbutamol32 34 9 18 9	13.8	KITLG, VCAM1, CHKB, CD79A, ITGB2, IL10
23	infliximab32 9 9	11.8	SELE, BGLAP, BAK1, ITGA4, FGF2, IL10
24	valine32	9.7	MTHFR, B2M, MPO, CD55, GSTM1, GSTP1
25	superoxide32 18	10.7	KITLG, GC, SELL, NAGLU, VCAM1, CHKB
26	ccl332	9.7	IL10, IL13, IL18, IL1A, IL1B, IL1R1
27	ascorbic acid32 18	10.6	VDR, BGLAP, CHKB, XRCC1, CGA, CD36
28	sulfasalazine32 9 9	11.5	SELE, MTHFR, MPO, CD79A, CD40LG, IL1A
29	pentoxifylline32 9 9	11.5	SELL, NAGLU, VCAM1, BMP6, MPO, ITGA4
30	rituximab32 34 9 9	12.4	BCL2, CD79A, CD59, CD40LG, CD80, CD40
31	homocysteine32 18	10.3	RETN, VWF, SELE, NAGLU, VCAM1, IL18
32	testosterone32 9 18 9	12.1	KITLG, GC, SELE, SERPINA7, VDR, VCAM1
33	vitamin a32 9 18 9	12.1	RETN, VWF, GC, SERPINA7, NAGLU, VDR
34	progesterone32 42 9 18 9	13.1	SERPINA7, BCL2, CGA, CDKN1B, CD55, GNAS
35	gm-csf32	9.0	KITLG, BMP6, IL10, IL13, IL18, IL1A
36	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32	9.0	MYC, BCL2, BAK1, BAX, CD40, IL1A
37	ly29400232	8.9	RETN, SELE, CD69, CDKN1B, ITGB2, FOS
38	1,25 dihydroxy vitamin d332	8.8	GC, VDR, MYC, BMP6, BGLAP, CDKN1B
39	rosiglitazone32 9 18 9	11.8	RETN, SELE, VCAM1, CD36, INS, IL18
40	etanercept32 9 9	10.7	FCGR2A, IL10, IL18, IL1B, IL1R1, IL1RN
41	15-deoxy-delta-12,14-prostaglandin j232	8.6	VCAM1, MYC, BMP6, CD36, FOS, FGF2
42	creatinine32	8.5	RETN, KITLG, VWF, GC, SELE, SELL
43	betacarotene32	8.5	VWF, MTHFR, XRCC1, CD79A, GSR, GSTM1
44	norepinephrine32 9 18 9	11.4	RETN, KITLG, VWF, SELE, SELL, VCAM1
45	folate32	8.3	VWF, SELE, VDR, VCAM1, MYC, MTHFR
46	daunorubicin32 9 9	10.3	KITLG, MYC, BCL2, BAX, MPO, CD36
47	lactate32	7.4	KITLG, VWF, BTD, SELE, SELL, NAGLU
48	pd 98,05932	7.4	KITLG, VCAM1, MYC, BMP6, BCL2, BAX
49	retinoid32	7.4	SELL, VDR, MYC, BMP6, BCL2, BAK1
50	tamoxifen32 34 9 9	9.2	SELE, SERPINA7, VDR, VCAM1, MYC, BMP6

Cellular components related to graves' disease according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	integral to plasma membrane	GO:005887	12.3	CD69, KIR2DL1, KIR2DL3, KIR3DS1, KIR2DS4, KIR3DL1
2	plasma membrane	GO:005886	11.1	TSHR, AIRE, HLA-A, HLA-B, HLA-C, HLA-DPB1
3	external side of plasma membrane	GO:009897	11.1	CXCR3, CD86, CD40LG, CD274, CD83, CD40
4	ER to Golgi transport vesicle membrane	GO:012507	10.8	HLA-G, HLA-DRB3, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1
5	integral to lumenal side of endoplasmic reticulum membrane	GO:071556	10.7	HLA-G, HLA-DRB3, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1
6	MHC class I protein complex	GO:042612	10.5	HLA-C, HLA-B, HLA-A, MICA, CD1A, B2M
7	cell surface	GO:009986	9.8	HSPA8, TPO, TNF, TNFRSF4, TNFSF4, PLAT
8	extracellular region	GO:005576	6.9	SIAE, GAST, CP, NPPB, NPPA, IFNG
9	extracellular space	GO:005615	6.3	SST, SPP1, CRP, PLAT, LTA, C4A

Biological processes related to graves' disease according to GeneDecks:

(show all 46)

id	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:006955	11.6	PDCD1LG2, FASLG, IL9, IL8, IL5, IL4R
2	T cell costimulation	GO:031295	11.5	CTLA4, HLA-DRB3, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1
3	interferon-gamma-mediated signaling pathway	GO:060333	11.4	HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB3, HLA-G
4	response to lipopolysaccharide	GO:032496	11.4	DIO2, CYP27B1, LTA, THBD, CXCL10, NKX2-1
5	regulation of immune response	GO:050776	11.4	B2M, VCAM1, SELL, KIR2DL2, KIR2DS1, KIR2DS2
6	leukocyte cell-cell adhesion	GO:007159	11.1	PTPRC, CALCA, ICAM1, CCL5, ITGB2, ITGAL
7	positive regulation of T cell proliferation	GO:042102	10.9	IL6, CCL5, IFNG, PTPRC, IL4, IL1B
8	somatostatin signaling pathway	GO:038170	10.9	SSTR5, SSTR4, SSTR3, SSTR2, SSTR1
9	cell-cell signaling	GO:007267	10.8	SSTR3, SSTR2, SSTR1, SST, TNFSF9, TRH
10	positive regulation of interleukin-12 production	GO:032735	10.8	TNFSF4, HLA-G, IDO1, IFNG, CD40, CD40LG
11	cell surface receptor signaling pathway	GO:007166	10.7	CBLB, PTPRC, SST, SSTR1, KLRB1, CXCL10
12	positive regulation of isotype switching to IgG isotypes	GO:048304	10.7	PTPRC, IFNG, IL4, IL2, CD40
13	cytokine-mediated signaling pathway	GO:019221	10.7	IRF1, B2M, VCAM1, FLNB, IL1A, IL1B
14	cellular response to mechanical stimulus	GO:071260	10.7	NFKB1, CASP8, FAS, IL1B, IL18, IL13
15	T cell receptor signaling pathway	GO:050852	10.6	NFKBIA, NFKB1, PTPRC, PTPN22, HLA-DRB3, HLA-DRB1
16	negative regulation of T cell proliferation	GO:042130	10.6	TGFB1, HLA-G, HLA-DRB3, HLA-DRB1, IL10, FOXP3
17	positive regulation of interferon-gamma production	GO:032729	10.5	LTA, TNFSF4, TNF, IL2, IL1B, IL18
18	B cell differentiation	GO:030183	10.5	TSHR, PTPRC, IL4, IL10, ITGA4, CD40LG
19	response to cold	GO:009409	10.4	ADRB2, CXCL10, PPARG, DIO2, TRH, CASP8
20	cellular response to lipopolysaccharide	GO:071222	10.3	NFKBIL1, TNFSF4, ICAM1, IFNG, CCR5, IL8
21	positive regulation of apoptotic process	GO:043065	10.2	TNF, PTPRC, CTLA4, SOD1, ADRB2, ADCY10
22	response to ethanol	GO:045471	10.1	CASP8, TRH, SOD1, NKX2-1, GNRH1, ICAM1
23	virus-host interaction	GO:019048	10.1	HLA-A, HLA-B, HLA-C, TP53, NFKBIA, KRT19
24	protein tetramerization	GO:051262	10.0	ACHE, TP53, HLA-DRB3, HLA-DRB1, CAT, IGF1R
25	positive regulation of osteoclast differentiation	GO:045672	10.0	CSF1, TNF, CA2, IFNG, CCL5, CCR1
26	positive regulation of B cell proliferation	GO:030890	10.0	PTPRC, TNFRSF4, IL5, IL4, IL2, IL13
27	defense response to virus	GO:051607	10.0	CXCL9, CXCL10, PTPRC, IFNG, IFNB1, IL6
28	positive regulation of immunoglobulin secretion	GO:051024	10.0	TNFSF4, TNFRSF4, IL6, IL5, IL2
29	humoral immune response	GO:006959	9.9	AIRE, TNF, LTA, ST6GAL1, IFNG, IFNB1
30	small molecule metabolic process	GO:044281	9.8	PLA2G6, CYP27B1, CYP2D6, CYP1A1, DIO2, DIO1
31	positive regulation of NF-kappaB transcription factor activity	GO:051092	9.7	TAB2, TGFB1, NFKBIA, NFKB1, TNF, CAT
32	response to heat	GO:009408	9.7	SOD1, SST, CALCA, CASQ1, HSPA4, IL1B
33	B cell proliferation	GO:042100	9.7	PTPRC, IFNB1, IL10, CD40, CD40LG, CD79A
34	signal transduction	GO:007165	9.6	TNFRSF18, TNFRSF11B, TRH, TXN, HLA-DRB3, ESR2
35	response to estrogen stimulus	GO:043627	9.6	CYP27B1, PPARG, KRT19, TSHB, TNFRSF11B, ESR1
36	female pregnancy	GO:007565	9.5	NPPA, TGFB1, THBD, GNRH1, GNAS, IDO1
37	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.2	TP53, IGF1, IL6R, IL6, IL5, IL3
38	response to drug	GO:042493	9.2	ICAM1, TNF, TNFRSF11B, SST, PPARG, LTA
39	response to gamma radiation	GO:010332	9.1	CXCL10, PTPRC, TP53, IL1B, IL1A, BAX
40	positive regulation of cell proliferation	GO:008284	9.0	FASLG, IGF1R, IGF1, TNFSF4, TSHR, TGFB1
41	anti-apoptosis	GO:006916	9.0	IGF1, GNRH1, TNF, TNFRSF18, NFKB1, NFKBIA
42	response to hypoxia	GO:001666	8.9	TNF, CRP, PLAT, LTA, TGFB1, NPPB
43	inflammatory response	GO:006954	8.7	CSF1, ADORA2A, NPPB, CXCL9, CXCL10, CCR3
44	negative regulation of cell proliferation	GO:008285	8.4	SST, CYP27B1, TNFRSF9, TNF, TP53, SSTR1
45	positive regulation of transcription, DNA-dependent	GO:045893	8.2	IL5, IL6, IGF1, AIRE, TP53, TNF
46	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.6	PPARG, TNF, TP53, AIRE, ESR1, IFNG

Molecular functions related to graves' disease according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	somatostatin receptor activity	GO:004994	10.6	SSTR1, SSTR2, SSTR3, SSTR4, SSTR5
2	cytokine activity	GO:005125	9.1	IL5, IL6, IL9, FASLG, IFNA2, IFNB1
3	hormone activity	GO:005179	8.9	TSHB, TG, POMC, NPPA, NPPB, GAST
4	growth factor activity	GO:008083	8.2	IL5, IL6, IL9, IGF1, TGFB1, CSF1
5	protein binding	GO:005515	5.3	HLA-DRB3, ACHE, TTR, TSHR, THBD, THRB